EASL Spotlight: Liver Docs Gear Up For Wave Of New Hep C Drugs, Expect Change Soon
Executive Summary
Publication of four Phase III studies for Gilead’s sofosbuvir in the New England Journal of Medicine reassures analysts on the safety front. But while Gilead is in the lead, its sofosbuvir-centered regimens will also face competition from several other promising new Hep C regimens in development.